Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?

The most active CROs are global operational providers rather than vaccine-only specialists. ICON/PRA, PPD / Thermo Fisher Scientific, and IQVIA together appeared in 23 trial-provider relationships across the 28 CRO-supported trials, indicating that sponsors mainly outsource execution scale, country operations, and specialist infrastructure rather than only therapeutic expertise.

The clearest CRO trigger is multi-country CTIS execution. Once vaccine trials expand beyond three European countries, CRO use becomes the dominant model. Single-country vaccine trials are mostly sponsor- or institution-run, with only 3 of 61 using CROs.

Vaccine CRO demand appears to be driven less by early safety work and more by late-stage operational load: site networks, country coordination, paediatric recruitment, safety reporting, clinical supplies, and EU/CTIS submission execution.

{"id":"05ff205e-0092-45fa-9af6-be9d1a0909c5","slug":"vaccine-phase-1-3-europe-cro-demand","status":"published","title":"Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?","html":"\u003c!--\n\"slug\": \"vaccine-phase-1-3-europe-cro-demand\",\n\"metaTitle\": \"EU Vaccine Phase 1 - 3 CRO Demand\",\n\"title\": \"Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?\",\n\"metaDescription\": \"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.\",\n\"keywords\": \"vaccine trials Europe, phase 1 - 3 vaccine trials, CRO vaccine trials, CTIS submissions, infectious disease vaccines, RSV vaccine trials, paediatric vaccine trials, EU trial outsourcing, vaccine trial sites, vaccine trial participants\"\n-->\n\n\u003cdiv style=\"background:#111315; color:#F2F2F2; font-family:Inter, ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; padding:48px 24px 72px 24px;\">\n\u003cdiv style=\"max-width:768px; margin:0 auto;\">\n\n\u003csection style=\"background:linear-gradient(180deg,#122319 0%,#111315 100%); border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:32px; margin-bottom:64px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:16px;\">\nClinical Trial Intelligence\n\u003c/div>\n\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?\">\n\n\u003ch1 style=\"font-size:48px; line-height:56px; font-weight:650; letter-spacing:-0.035em; margin:0 0 12px 0; color:#F2F2F2;\">\nWhere Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?\n\u003c/h1>\n\n\u003cdiv style=\"font-size:13px; line-height:1.5; font-weight:600; color:#3FAE6F; margin:0 0 22px 0;\">\n23 June 2026\n\u003c/div>\n\n\u003cp style=\"font-size:17px; line-height:1.65; font-weight:400; color:rgba(255,255,255,0.70); margin:0 0 28px 0;\">\nAcross 101 European CTIS-authorised vaccine phase 1 - 3 trials, 28 trials used at least one CRO or CRO-like outsourced operating partner, equal to 27.7% of the cohort. CRO use concentrates in larger execution models: 16 of 19 trials with 4+ countries used CROs, 14 of 22 trials with 20+ sites used CROs, and 5 of 7 trials with 1,000+ participants used CROs. ICON/PRA was the most active named provider with 9 supported trials, followed by PPD / Thermo Fisher Scientific with 8 and IQVIA with 6.\n\u003c/p>\n\n\u003c/div>\n\n\u003cdiv style=\"display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:16px;\">\n \u003cdiv style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n \u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.50); text-transform:uppercase; letter-spacing:0.08em;\">Trials analysed\u003c/div>\n \u003cdiv style=\"font-size:34px; font-weight:650; color:#F2F2F2; margin-top:6px;\">101\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">European vaccine phase 1 - 3 trials\u003c/div>\n \u003c/div>\n \u003cdiv style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n \u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.50); text-transform:uppercase; letter-spacing:0.08em;\">CRO-supported\u003c/div>\n \u003cdiv style=\"font-size:34px; font-weight:650; color:#3FAE6F; margin-top:6px;\">28 / 101\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">27.7% of vaccine trials\u003c/div>\n \u003c/div>\n \u003cdiv style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n \u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.50); text-transform:uppercase; letter-spacing:0.08em;\">Largest CRO trigger\u003c/div>\n \u003cdiv style=\"font-size:34px; font-weight:650; color:#3FAE6F; margin-top:6px;\">84.2%\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">16 / 19 trials with 4+ countries used CROs\u003c/div>\n \u003c/div>\n \u003cdiv style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n \u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.50); text-transform:uppercase; letter-spacing:0.08em;\">Most active provider\u003c/div>\n \u003cdiv style=\"font-size:34px; font-weight:650; color:#F2F2F2; margin-top:6px;\">ICON / PRA\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">9 CRO-supported vaccine trials\u003c/div>\n \u003c/div>\n\u003c/div>\n\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Which CROs are most active?\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nWhich CROs are most active in vaccine phase 1 - 3 trials?\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nICON/PRA supported 9 of 28 CRO-supported vaccine trials, equal to 32.1% of CRO-supported trials. PPD / Thermo Fisher Scientific supported 8 of 28 trials, IQVIA supported 6 of 28, and Almac supported 4 of 28.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Top CROs and outsourced operating partners\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nShare of CRO-supported trials\n\u003c/div>\n\n\u003cdiv style=\"display:grid; gap:14px;\">\n \u003cdiv>\n \u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>ICON / PRA\u003c/span>\u003cspan>9 / 28 · 32.1%\u003c/span>\u003c/div>\n \u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:32.1%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\n \u003c/div>\n \u003cdiv>\n \u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>PPD / Thermo Fisher Scientific\u003c/span>\u003cspan>8 / 28 · 28.6%\u003c/span>\u003c/div>\n \u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:28.6%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\n \u003c/div>\n \u003cdiv>\n \u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>IQVIA\u003c/span>\u003cspan>6 / 28 · 21.4%\u003c/span>\u003c/div>\n \u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:21.4%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\n \u003c/div>\n \u003cdiv>\n \u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Almac\u003c/span>\u003cspan>4 / 28 · 14.3%\u003c/span>\u003c/div>\n \u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:14.3%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\n \u003c/div>\n \u003cdiv>\n \u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Syneos Health\u003c/span>\u003cspan>3 / 28 · 10.7%\u003c/span>\u003c/div>\n \u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:10.7%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\n \u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\nCROs and outsourced operating partners explicitly marked in CTIS sponsor records; one trial may list more than one provider.\n\u003c/div>\n\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Which CROs are most active?\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">\nThe most active CROs are global operational providers rather than vaccine-only specialists. ICON/PRA, PPD / Thermo Fisher Scientific, and IQVIA together appeared in 23 trial-provider relationships across the 28 CRO-supported trials, indicating that sponsors mainly outsource execution scale, country operations, and specialist infrastructure rather than only therapeutic expertise.\n\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"At what capacity level are CROs needed most?\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nAt what capacity level are CROs needed most?\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nCRO demand rises sharply with operating scale. CRO-supported trials averaged 5.1 countries, 32.1 sites, and 810.1 participants, compared with 1.4 countries, 8.2 sites, and 203.5 participants for trials without CROs.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"CRO use by operational scale\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nCRO use by scale threshold\n\u003c/div>\n\n\u003ctable style=\"width:100%; border-collapse:collapse; font-size:14px;\">\n \u003cthead>\n \u003ctr>\n \u003cth style=\"text-align:left; padding:10px; color:rgba(255,255,255,0.55); border-bottom:1px solid rgba(255,255,255,0.10);\">Capacity level\u003c/th>\n \u003cth style=\"text-align:right; padding:10px; color:rgba(255,255,255,0.55); border-bottom:1px solid rgba(255,255,255,0.10);\">CRO-supported\u003c/th>\n \u003cth style=\"text-align:right; padding:10px; color:rgba(255,255,255,0.55); border-bottom:1px solid rgba(255,255,255,0.10);\">Share\u003c/th>\n \u003c/tr>\n \u003c/thead>\n \u003ctbody>\n \u003ctr>\u003ctd style=\"padding:10px; border-bottom:1px solid rgba(255,255,255,0.07);\">4+ countries\u003c/td>\u003ctd style=\"padding:10px; text-align:right; border-bottom:1px solid rgba(255,255,255,0.07);\">16 / 19\u003c/td>\u003ctd style=\"padding:10px; text-align:right; color:#3FAE6F; border-bottom:1px solid rgba(255,255,255,0.07);\">84.2%\u003c/td>\u003c/tr>\n \u003ctr>\u003ctd style=\"padding:10px; border-bottom:1px solid rgba(255,255,255,0.07);\">1,000+ participants\u003c/td>\u003ctd style=\"padding:10px; text-align:right; border-bottom:1px solid rgba(255,255,255,0.07);\">5 / 7\u003c/td>\u003ctd style=\"padding:10px; text-align:right; color:#3FAE6F; border-bottom:1px solid rgba(255,255,255,0.07);\">71.4%\u003c/td>\u003c/tr>\n \u003ctr>\u003ctd style=\"padding:10px; border-bottom:1px solid rgba(255,255,255,0.07);\">20+ sites\u003c/td>\u003ctd style=\"padding:10px; text-align:right; border-bottom:1px solid rgba(255,255,255,0.07);\">14 / 22\u003c/td>\u003ctd style=\"padding:10px; text-align:right; color:#3FAE6F; border-bottom:1px solid rgba(255,255,255,0.07);\">63.6%\u003c/td>\u003c/tr>\n \u003ctr>\u003ctd style=\"padding:10px; border-bottom:1px solid rgba(255,255,255,0.07);\">2 - 3 countries\u003c/td>\u003ctd style=\"padding:10px; text-align:right; border-bottom:1px solid rgba(255,255,255,0.07);\">9 / 21\u003c/td>\u003ctd style=\"padding:10px; text-align:right; color:#3FAE6F; border-bottom:1px solid rgba(255,255,255,0.07);\">42.9%\u003c/td>\u003c/tr>\n \u003ctr>\u003ctd style=\"padding:10px;\">1 country\u003c/td>\u003ctd style=\"padding:10px; text-align:right;\">3 / 61\u003c/td>\u003ctd style=\"padding:10px; text-align:right; color:#3FAE6F;\">4.9%\u003c/td>\u003c/tr>\n \u003c/tbody>\n\u003c/table>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\nCapacity measured at trial level using number of participating countries, total sites, and total participants.\n\u003c/div>\n\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"At what capacity level are CROs needed most?\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">\nThe clearest CRO trigger is multi-country CTIS execution. Once vaccine trials expand beyond three European countries, CRO use becomes the dominant model. Single-country vaccine trials are mostly sponsor- or institution-run, with only 3 of 61 using CROs.\n\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Which phases rely most on CROs?\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nWhich vaccine trial phases rely most on CROs?\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nCRO support is concentrated in later-stage vaccine development. Phase 3 trials had the highest absolute CRO use, with 16 of 37 phase 3 trials supported by CROs, equal to 43.2%. Pure phase 1 trials had 0 of 23 CRO-supported trials.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"CRO use by phase\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nCRO-supported share by phase label\n\u003c/div>\n\n\u003cdiv style=\"display:grid; gap:14px;\">\n \u003cdiv>\u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Phase 3\u003c/span>\u003cspan>16 / 37 · 43.2%\u003c/span>\u003c/div>\u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:43.2%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003c/div>\n \u003cdiv>\u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Phase 2 - 3\u003c/span>\u003cspan>2 / 6 · 33.3%\u003c/span>\u003c/div>\u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:33.3%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003c/div>\n \u003cdiv>\u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Phase 2\u003c/span>\u003cspan>6 / 20 · 30.0%\u003c/span>\u003c/div>\u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:30.0%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003c/div>\n \u003cdiv>\u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Phase 1 - 2\u003c/span>\u003cspan>3 / 13 · 23.1%\u003c/span>\u003c/div>\u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:23.1%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003c/div>\n \u003cdiv>\u003cdiv style=\"display:flex; justify-content:space-between; font-size:14px; margin-bottom:6px;\">\u003cspan>Phase 1\u003c/span>\u003cspan>0 / 23 · 0.0%\u003c/span>\u003c/div>\u003cdiv style=\"height:10px; background:#24282C; border-radius:999px;\">\u003cdiv style=\"width:0%; height:10px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\nPhase labels normalized from CTIS trial-stage values; phase 2 - 4 trials are not shown in the chart but accounted for in the 101-trial cohort.\n\u003c/div>\n\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Which phases rely most on CROs?\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">\nVaccine CRO demand appears to be driven less by early safety work and more by late-stage operational load: site networks, country coordination, paediatric recruitment, safety reporting, clinical supplies, and EU/CTIS submission execution.\n\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Which indications need CROs most?\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nWhich indications and diseases need CRO support most?\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nInfectious disease had the largest absolute CRO need, with 18 of 52 infectious disease vaccine trials using CROs. By grouped disease, RSV had the largest absolute CRO-supported footprint with 5 of 10 trials using CROs, while group B streptococcus and influenza each had 3 CRO-supported trials.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"CRO use by indication\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nIndication and disease-level CRO demand\n\u003c/div>\n\n\u003cdiv style=\"display:grid; grid-template-columns:1fr 1fr; gap:16px;\">\n \u003cdiv style=\"background:#111315; border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-bottom:10px;\">Therapeutic area\u003c/div>\n \u003cdiv style=\"font-size:22px; font-weight:650; color:#3FAE6F;\">18 / 52\u003c/div>\n \u003cdiv style=\"font-size:14px; color:#F2F2F2; margin-top:4px;\">Infectious Disease\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">34.6% CRO-supported\u003c/div>\n \u003c/div>\n \u003cdiv style=\"background:#111315; border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-bottom:10px;\">Largest disease footprint\u003c/div>\n \u003cdiv style=\"font-size:22px; font-weight:650; color:#3FAE6F;\">5 / 10\u003c/div>\n \u003cdiv style=\"font-size:14px; color:#F2F2F2; margin-top:4px;\">RSV vaccine trials\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">50.0% CRO-supported\u003c/div>\n \u003c/div>\n \u003cdiv style=\"background:#111315; border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-bottom:10px;\">High CRO intensity\u003c/div>\n \u003cdiv style=\"font-size:22px; font-weight:650; color:#3FAE6F;\">3 / 3\u003c/div>\n \u003cdiv style=\"font-size:14px; color:#F2F2F2; margin-top:4px;\">Group B streptococcus\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">100.0% CRO-supported\u003c/div>\n \u003c/div>\n \u003cdiv style=\"background:#111315; border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-bottom:10px;\">High CRO intensity\u003c/div>\n \u003cdiv style=\"font-size:22px; font-weight:650; color:#3FAE6F;\">3 / 3\u003c/div>\n \u003cdiv style=\"font-size:14px; color:#F2F2F2; margin-top:4px;\">Influenza\u003c/div>\n \u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:4px;\">100.0% CRO-supported\u003c/div>\n \u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\nDisease groups were normalized from CTIS disease fields and counted at trial level.\n\u003c/div>\n\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Which indications need CROs most?\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20p","excerpt":"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.","coverImageUrl":null,"coverImageAlt":null,"author":null,"category":null,"tags":[],"metaTitle":"EU Vaccine Phase 1 - 3 CRO Demand","metaDescription":"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.","canonicalUrl":null,"robots":"index,follow","keywords":["vaccine trials Europe","phase 1 - 3 vaccine trials","CRO vaccine trials","CTIS submissions","infectious disease vaccines","RSV vaccine trials","paediatric vaccine trials","EU trial outsourcing","vaccine trial sites","vaccine trial participants"],"ogTitle":"EU Vaccine Phase 1 - 3 CRO Demand","ogDescription":"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.","ogImageUrl":"https://trialagents.com/og-default.png","ogImageAlt":"Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?","ogType":"article","twitterCard":"summary_large_image","twitterTitle":"EU Vaccine Phase 1 - 3 CRO Demand","twitterDescription":"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.","twitterImageUrl":"https://trialagents.com/og-default.png","schemaJsonLd":{"@context":"https://schema.org","@graph":[{"@type":"Article","headline":"Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?","description":"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.","datePublished":"2026-07-05","dateModified":"2026-07-05","author":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"},"publisher":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"},"mainEntityOfPage":"https://trialagents.com/reports/vaccine-phase-1-3-europe-cro-demand"},{"@type":"Dataset","name":"Where Are CROs Most Active in European Vaccine Phase 1 - 3 Trials?","description":"Among 101 EU vaccine trials, 28 used CROs; ICON/PRA led with 9, and CRO use reached 84.2% in 4+ country trials.","variableMeasured":["Top CROs and outsourced operating partners","CRO use by operational scale","CRO use by phase","CRO use by indication"],"spatialCoverage":"Europe","isAccessibleForFree":true,"license":"https://creativecommons.org/licenses/by/4.0/","creator":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"}}]},"publishedAt":"2026-07-05T07:49:48.578Z","createdAt":"2026-07-05T07:49:48.712Z","updatedAt":"2026-07-05T07:49:48.712Z"}